SEC Form 4 · accession 0001610717-26-000221
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Grais
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.60 | Jun 11, 2026 | A | 15,000 | A | — | Jun 11, 2036 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.